Nigrostriatal Dopamine Terminals In Parkinson'S Disease plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Nigrostriatal terminals are the axon terminals of substantia nigra pars compacta (SNpc) dopaminergic neurons that project to the striatum (caudate and putamen). These terminals are the primary site of neurodegeneration in Parkinson's disease (PD).
- Terminals: En passant synapses on striatal dendrites and spines
- Release mechanism: Vesicular exocytosis, quantal release
- Receptor modulation: Acts on D1 (direct) and D2 (indirect) pathways
- Plasticity: Activity-dependent modulation of release
- Direct pathway (D1): Facilitate movement initiation
- Indirect pathway (D2): Suppress competing movements
- Balance: D1/D2 signaling equilibrium enables smooth movement
- Learning: Reward prediction error signaling
- Earliest change: Terminal loss precedes cell body death
- Denervation: Complete striatal dopamine depletion
- Terminal dysfunction: Impaired release before degeneration
- Compensatory mechanisms: Increased firing, sprouting
- Axonal transport defects: Dysfunction of dynein/dynactin
- Mitochondrial deficits: Complex I deficiency in terminals
- Oxidative stress: High dopamine oxidation
- Alpha-synuclein toxicity: Oligomers impair function
- DaTscan: Reduced dopamine transporter binding
- FDG-PET: Abnormal metabolic patterns
- MRI: Increased iron deposition
- Bradykinesia: Correlates with putamen dopamine loss
- Rigidity: Related to D2 pathway dysfunction
- Resting tremor: More variable correlation
- Levodopa response: Terminals convert to dopamine
- Dyskinesias: From pulsatile receptor stimulation
- Wearing off: Reflects terminal reserve
- Growth factors: GDNF, BDNF for terminal preservation
- Gene therapy: AADC gene delivery
- Cell replacement: Dopaminergic cell transplantation
- Viral vectors: Restore dopamine synthesis
- Optogenetic stimulation: Patterned activation
- Chemogenetic modulation: DREADD-based approaches
Nigrostriatal Dopamine Terminals In Parkinson'S Disease plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Nigrostriatal Dopamine Terminals In Parkinson'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Surmeier et al., SNc vulnerability in PD (2024)
- Caudron et al., Nigrostriatal terminal degeneration (2023)
- Jankovic, Motor symptoms correlation (2022)
- Barker et al., Cell therapy for PD (2020)
- Kalia & Lang, PD neuroprotection strategies (2024)